Shares in Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) jumped 19% on Friday, extending a remarkable 169% gain over the week, after the London-listed longevity company reported encouraging progress in its gene therapy trial aimed at slowing ageing in dogs.
The company said its experimental SIRT6 therapy, based on a genetic variant found in people who live beyond 100, had been safely administered for a second time to elderly beagles with no side effects observed. The study, involving 28 dogs aged ten and older, is due to conclude in January 2026.
The trial is testing whether the SIRT6 gene can improve DNA repair and metabolic regulation, two processes that weaken with age. Results so far show an “excellent safety and tolerability profile”, bolstering confidence in the therapy’s potential.
Genflow is the only publicly listed longevity company in Europe and believes success in animals could open the door to a new segment of the multibillion-dollar animal health market.
The company also sees the research as an early step toward applying the same approach to human health.
Chief executive Dr Eric Leire said: “We’re very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we’re seeing from established players in the animal health industry.”
With repeat dosing now confirmed as safe, Genflow plans to advance its animal health research and seek partnerships with larger pharmaceutical and veterinary companies.
The group said it remains focused on gene-based treatments to extend both health and lifespan.